KALA BIO (KALA)
NASDAQ:KALA
Want to see KALA full AI Analyst Report?
KALA Stock Chart & Stats
$0.62
-$0.34(-4.42%)
At close: 4:00 PM EST
$0.62
-$0.34(-4.42%)
Day’s Range― - ―
52-Week Range$0.10 - $20.60
Previous CloseN/A
Volume15.45K
Average Volume (3M)1.94M
Market Cap
$106.98M
Enterprise Value-$5.03M
Total Cash (Recent Filing)$7.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)1.6
Beta1.75
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.17
Shares Outstanding929,491,600
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.14
Enterprise Value/Market Cap-0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit93.20
Enterprise Value/Ebitda0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic AI Platform License (recurring Revenue Potential)The exclusive Researgency license creates a structural shift from pure drug discovery to platform SaaS/PaaS revenues. An on‑premises, data‑sovereign offering targets an underpenetrated, multibillion‑dollar biotech R&D niche and can generate sticky, recurring revenue and higher gross margins over time.
Meaningful Deleveraging (debt Reduced To Zero)Eliminating debt materially lowers fixed financial obligations and default risk, improving solvency and strategic flexibility. This gives management time to execute pivots (like the AI platform) without interest burdens, supporting longer‑term operations and potential non‑dilutive partnerships.
Demonstrated Access To Financing And Shareholder ApprovalsRecent private placements and shareholder approvals show the company can raise capital and secure governance actions to maintain listing compliance. This improves near‑term funding optionality to support platform deployment and R&D while enabling planned corporate actions.
Bears Say
Zero Revenue And Persistent Operating LossesThe absence of any revenue base leaves the company exposed to continued burn and execution risk; operating losses remain large and fixed costs are not absorbed. Without durable revenue, long‑term viability depends on successful platform commercialization or continual external funding.
Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicate the business is structurally cash‑consumptive. This undermines runway, forces repeat financings (dilutive or costly), and constrains the ability to invest in sales, development, or platform scale without external capital.
Compressed Equity/base Assets And High Dilution RiskA shrunken asset and equity base reduces financial resilience and magnifies dilution impact from convertible financings and increased authorized shares. Potential conversion of preferred stock and authorized share expansion could materially dilute existing holders and weaken per‑share economics long term.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $0.10 and its highest was $20.60 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $106.98M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is May 19, 2026 which is in 12 days.
How were KALA BIO’s earnings last quarter?
KALA BIO released its earnings results on Mar 26, 2026. The company reported $0.025 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.345.
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 929,491,600 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
KALA BIO reported an EPS of $0.025 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went down -6.542%.
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KALA BIO Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 795.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.36%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
-82.90%
Trailing 12-Months
Company Description
KALA BIO
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Technical Analysis
Ownership Overview
0.08% Insiders
0.01% Mutual Funds
<0.01% Other Institutional Investors
99.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---